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Abstract
Background: We sought to assess whether GFS, a proprietary preparation of Tasmanian Undaria
pinnatifida, has effects on healing or re-emergence of Herpetic infections, and additionally, to assess
effects of GFS in vitro. Undaria is the most commonly eaten seaweed in Japan, and contains sulphated
polyanions and other components with potential anti-viral activity. Herpes simplex virus type 1
(HSV-1) infections have lower reactivation rates and Herpes type 2 (HSV-2) infections have lower
incidence in Japan than in the west.
Methods: Patients with active (15 subjects) or latent (6 subjects) Herpetic infections (HSV-1, 2,
EBV, Zoster) were monitored for response to ingestion of GFS. GFS extract was tested in vitro for
human T cell mitogenicity and anti-Herpes activity.
Results: Ingestion of GFS was associated with increased healing rates in patients with active
infections. In addition, patients with latent infection remained asymptomatic whilst ingesting GFS.
GFS extract inhibited Herpes viruses in vitro and was mitogenic to human T cells in vitro.
Conclusions:  Ingestion of GFS has inhibitory effects on reactivation and is associated with
increased rate of healing after Herpetic outbreaks. GFS extract potently inhibited Herpes virus in
vitro, and had mitogenic effects on human T cells.
Background
Herpes viruses are important human pathogens, causing
both primary and secondary infections that range from
trivial mucosal ulcers to life threatening disorders in im-
muno-compromised patients [1,2]. The Herpes group in-
cludes HSV-1, HSV-2, Herpes Zoster (chicken pox/
shingles), HCMV (human cytomegalovirus), EBV, Herpes
6, 7 (Roseola, post transplant infections) and Herpes 8
(associated with Kaposi sarcoma). The conventional treat-
ment of these infections is with drugs such as acyclovir
(ACV) that target the viral DNA polymerase. Whilst these
drugs are undoubtedly efficient, their long-term use has
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led to the development of resistant viral strains that now
comprise 5% of all HSV infections in immuno-compro-
mised patients [1]. Finding non-toxic alternatives to these
drugs is of interest to patients and to drug companies in-
vestigating more effective remedies. Whilst the epidemiol-
ogy and serotype of Herpes infections varies widely within
the world community, as a result of differing subpopula-
tions and childhood exposure rates, it seems that the inci-
dence of HSV2 in Japanese women is substantially less
than that of American women. (e.g., 50% seroprevalence
in one study of African-American women vs. 7% in Japan)
[3]. We also noted that the reactivation of Herpes simplex
I (HSV-1) as measured by shedding [4] is considerably less
in the Japanese population than in the west. However,
EBV, some strains of which are associated with malignan-
cies, affects over 90% of the population world wide [5],
and seropositivity for CMV is higher in the Japanese pop-
ulation [6].
Several plants have been shown to have anti-viral activity,
but edible brown marine algae are unique in that they are
a regular part of the Japanese daily diet. Key anti-viral ac-
tive agents within brown algae are the sulphated poly-
anions [7–9]. In recent years both natural and synthetic
sulphated polyanions have been a research focus for their
potential therapeutic activity. They are considered to act
principally by inhibiting the entry of coated viruses such
as Herpes into host cells [7–9], by competing for receptors
at the cell surface. This activity is, in part, due to the simi-
larities of the algal polyanions to mammalian heparin sul-
phate molecules. There are a number of receptors
(including a heparin sulphate receptor) expressed differ-
entially on various cell types, which provide entry points
for Herpes viruses [10]. This mechanism of inhibition
contrasts with that of commonly used drugs such as ACV
which act as nucleic acid inhibitors, preventing viral repli-
cation after the virus has entered the cell.
The main seaweed in the Japanese daily diet is Undaria
pinnatifida, commonly known as 'wakame' [11]. The ma-
jor sulphated polyanion present in Undaria is character-
ised as a 'galactofucan sulphate' [12,13]. Other sulphated
polyanions such as the synthetic dextran sulphates, pen-
tosan sulphates, clinically used heparins, and seaweed-de-
rived carageenans have all been investigated for anti-viral
activity in humans, either systemically or topically [7–9].
However, to date, Undaria ingestion has not been clinical-
ly assessed in a western population for its effects on com-
mon coated viruses such as HSV-1 and 2 which have
reduced incidence in the Japanese population [3,4]. Unda-
ria extracts have been shown to have anti-viral effects on
HSV-1 in vitro [14] and also against the Herpes group virus
Epstein Barr Virus or EBV [15]. Specific molecules were
not identified in these studies, thus the observed anti-viral
activity may arise from either or both polyanions and oth-
er components. Undaria aqueous extract (made by boil-
ing Undaria in water) and a partially purified galactofucan
sulphate extract were recently assessed for activity against
clinical isolates of Herpes I and Herpes II in vitro [16,17].
Twenty of the viral strains were sensitive to ACV, and nine-
teen were resistant. In the test, both types of extract were
active against all strains, and more active against strains of
HSV-2 than strains of HSV-1. The mode of action was
shown to be blocking attachment and entry of HSV into
the host cells.
Undaria fractions have also been shown to have immune
stimulating qualities in vitro [18] and other brown sea-
weed fractions have been shown to have immunological
effects in vivo [19,8,9].
The mechanism of viral inhibition by polyanions such as
galactofucan does not generate resistant strains at the
same rates as ACV [7]. Aside from the inhibition of viral
infectivity, it is possible that immune stimulation via
polyanions or other components, increases anti-viral ac-
tivity [18,19]
We hypothesised that Undaria ingestion may be associat-
ed with resolution of Herpes infections in a western pop-
ulation, and that this would be reflected by inhibition of
HSV infectivity and increased T cell activity in vitro. In this
study, a proprietary Undaria  preparation 'GFS' was as-
sessed for effects on the healing of, and the inhibition of
outbreaks of HSV infections in otherwise healthy patients.
In addition, whole aqueous extracts of the GFS were as-
sessed for effects on HSV infectivity in vitro and on human
T cell stimulation in vitro.
Methods
A) GFS
GFS was prepared from Tasmanian Undaria pinnatifida
and supplied in 560 mg capsules by Marine Resources Pty
Ltd. It comprises solely of the alga, processed to complete
dryness in the dark within a day of harvest, in hygienic
conditions. Batches were milled and mixed to ensure uni-
formity.
B) Patient study
Seventeen patients were recruited for the study by health
practitioners. Patients gave verbal informed consent to the
study. Health practitioners monitored the patients'
health. There are no known adverse effects related to the
ingestion of Undaria. No other anti-viral medications were
taken at the same time as GFS. The duration of the study
was from one month to 24 months. Patient ages were
from less than 10 years up to 72 years.
In total, seven cases of HSV-1, five cases of HSV-2, three of
active Herpes zoster (one chicken pox, two shingles) andBMC Complementary and Alternative Medicine 2002, 2 http://www.biomedcentral.com/1472-6882/2/11
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two of EBV were assessed. Results are presented in tables
1 and 2. Patients suffering from HSVI typically experi-
enced lesions lasting ten days. Patients with HSVII had ex-
perienced recurrent events of varying severity, sometimes
overlapping, of up to ten days in duration. One patient
with shingles reported 'cycle' duration of over ten days.
Others did not report on duration.
Dosage levels were chosen to fall within the limits of nor-
mal dietary seaweed ingestion in Japan. Fifteen patients
with active Herpetic viral infections were given four 560
mg capsules of GFS per day for ten days as a 'therapeutic
dose'. All patients except subject 14, table 1 (primary
zoster infection) were suffering repeat outbreaks of
known aetiology
Six patients with latent HSV-1 or 2 were given two cap-
sules per day as a 'maintenance dose'. Four of these pa-
tients, identified by an asterisk *, were continuations of
treatment after the active infection phase. One patient
(subject 3, table 2) took four capsules per day.
Table 1: Patients with active Herpes infections
Patient Sex Age Virus Site infection Resolution of 
infection?
If on 
maintenance, 
Inhibition of 
outbreaks?
Comment
1 M 50 HSVI Orolabial Yes, no progression to 
lesion
Yes, inhibition of 
further outbreaks 
on maintenance 
dose >2 years.
Varied dosage, consistent 
inhibition.
2 F 14 HSV1 Orolabial Yes, very severe 
outbreak resolved within 
course.
N/a Patient noted rapid reduction 
in pain.
3 F 72 HSVI prodrome Orolabial 
(prodrome) 
and ocular 
conjunctiva
Yes, no progression to 
lesion
Yes, continued 
Inhibition of low 
grade conjunctival 
HSVI for three 
months
Notes improvement in skin 
condition.
4 M 40 HSVI prodrome Orolabial Yes, in normal time. N/a Not taken consistently. No 
benefit noted but no spread 
of lesion.
5 F 50 HSVI active lesion Orolabial Yes, in normal time N/a No spread of lesion and pain 
reduced. Took half dose only.
6. F 47 HSVI Orolabial Yes, reduction in lesion 
severity
N/a No recurrence, no spread of 
lesion.
7. F 47 HSVI Orolabial Yes, rapid clearance 
compared to previous.
N/a Post chemotherapy outbreak 
(breast cancer)
8 F 20 HSVII Genital Yes, lesions cleared. N/a
9 F 42 HSVII Genital Yes. Existing lesion 
healed.
Yes, inhibition of 
further outbreaks 
on maintenance 
dose 3 mths.
Prior two weekly outbreaks 
of ACV resistant strain of 
HSVII.
10 F 23 HSVII Genital Yes, chronic lesion 
healed
N/a
11 F 17 EBV systemic Yes N/a Normal blood exam after 4 
days course.
12 F <10 EBV Systemic Yes, EBV symptoms 
absent at ten days
N/a Three capsules per day 
Chronic sinus infection also 
cleared
13 F 85 Zoster (shingles) Torso Yes Yes, inhibition for 
two months.
Relief from lesions at 4 
capsules per day
14. M Adult Zoster (chicken pox) Whole body 
sores
Yes N/a Pain reduction, rapid clearing 
of lesions.
15 M 40 Zoster (shingles) T7,8, 
dermatome 
Right side
Yes N/a Faster drying of lesions, 
increased speed of cycle, no 
change in painBMC Complementary and Alternative Medicine 2002, 2 http://www.biomedcentral.com/1472-6882/2/11
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C) In vitro effects on HSV
GFS was mixed 1:40 w/v with distilled water and boiled
for 5 minutes. The liquid was filtered through a 0.45 µM
filter for sterilization and stored at -20 degrees Celsius. An
aliquot of the preparation was dried and the weight was
obtained to determine the concentration. The concentra-
tion used was the dry weight of the dissolved solids
present.
Immortalized human fibroblasts, HF cells, were grown in
Minimal Essential Media supplemented with glutamine,
antibiotics, and 10% foetal bovine serum (FBS). Mainte-
nance medium was supplemented with 1% FBS. Labora-
tory strains of HSV and HCMV (American type culture
collection) were tested in this study. A stock of each virus
was grown in cultured HF cells and aliquots were frozen
at -70°C. The titre of each virus was determined by a
plaque assay using HF cells in 24-well plates with an aga-
rose overlay.
D) T cell stimulation in vitro
T cell mitogenicity was evaluated by chromium uptake.
Whole T cell preparations were obtained from buffy coats
from pooled human blood samples. They were incubated
in RPMI supplemented with 10% heat inactivated foetal
calf serum, 5 mM L-glutamine, 5 × 10 -5 M 2-mercaptoeth-
anol and 30 U/ml gentamycin. Incubation for 72 hours
was at 5%CO2, 37°C in 24 well plates. Cells were incubat-
ed with either GFS whole extract (at 25, 125 and 250 mcg/
ml as 1%, 5% or 10% of total culture volume prepared
from a stock solution at 2.5 mg/ml) or with the known
mitogens (PHA) (1 mcg/ml) or Concanavalin A (ConA)
(1 mcg/ml). Each concentration was assessed in triplicate
(n = 3)
Results
Patient study
Results are presented in tables 1 and 2.
Active infection-table 1
All fifteen patients with active Herpetic viral infections ex-
perienced significant lessening or disappearance of symp-
toms. No adverse side effects were noted during the study.
Two patients (subjects 4 and 5, table 1) with noncompli-
ant dosage regimes resolved infections in normal time,
but noted no spread of lesions (as occurred during previ-
ous outbreaks). Reduction in lesion severity and rapid
clearance were noted in two patients (subjects 6,7, table
1), and pain reduction as compared to previous events
was noted by two patients (subjects 2,14, table 1). Two fe-
males with genital HSV-2 had persistent lesions which re-
solved during the course of treatment (subjects 8,10, table
1).
In two cases of diagnosed EBV, one clear at four and the
other by ten days. In the latter patient a chronic sinus con-
dition also cleared (subjects 11,12, table 1)
Over ten days, faster drying of zoster lesions and increased
speed of normal cycle as compared to previous outbreaks
was noted by a male patient (subject 15, table 1) although
Table 2: Patients with latent Herpes infections.
patient sex age virus Site of
infection
Also treated for active 
infection?
Inhibition of outbreak whilst on 
maintenance dose?
Comments
1 M* (1) 50 HSVI Orolabial Yes Existing lesion 
healed.
Yes, inhibition of further 
outbreaks on maintenance dose 
>2 years.
Varied dosage, consistent 
inhibition.
2F *  ( 3 ) 7 2 H S V I
prodrome
Orolabial 
(prodrome) 
and ocular 
conjunctiva
Yes, no progression to 
lesion
Yes, continued Inhibition of low 
grade conjunctival HSVI for 
three months
Notes improvement in skin 
condition.
3 F* (13) 85 Zoster 
(shingles)
Torso Yes Yes, inhibition for two months. Relief from lesions requires 4 
capsules per day
4 F* (9) 42 HSVII Genital Yes. Existing lesion 
healed.
Yes, inhibition of further 
outbreaks on maintenance dose 
3 months.
Prior two weekly outbreaks of 
ACV resistant strain of HSVII.
5 F 41 HSVII Genital No(not taken during 
active infection)
Yes, inhibition on two capsules 
per day for 1 month.
Did not take during active 
lesion outbreak.
6 F 36 HSVII Genital No(not taken during 
active infection)
Yes, inhibition on two capsules 
per day for 1 month.
Did not take during active 
lesion outbreak.
* the number in brackets refers to the number assigned to the same patient in table 1.BMC Complementary and Alternative Medicine 2002, 2 http://www.biomedcentral.com/1472-6882/2/11
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no reduction in pain was reported. In an adult male suf-
fering primary zoster (chicken pox) lesions of whole body
(subject 14, table 1), pain reduction and rapid healing of
lesions were noted. An elderly female patient noted a re-
duction in pain and visible skin lesions during the ten day
course, and had no recurrence of symptoms whilst on a
lower dose for the next two months.
Latent infections-table 2
All six patients on maintenance doses noted inhibition of
further outbreaks of infection. No adverse side effects
were noted during the study.
HSV-1 outbreaks were inhibited in two patients taking a
maintenance dose over three months and two years re-
spectively (subjects 1 and 2 in table 2). Low grade HSV-1
associated keratoconjunctivitis in the former patient was
also inhibited
GFS ingestion correlated with inhibition of a previously
persistent HSV-2 infection for three months in subject 4,
table 2. In this patient, the infection was ACV resistant and
outbreaks had been apparent on a two weekly basis for
over a year.
HSV-2 outbreaks at the genital site were inhibited in two
other female patients whilst taking a maintenance dose of
two capsules per day, for one month (subjects 5,6, table
2).
Low grade recurrent Herpes zoster (shingles) lesions of
the torso were inhibited for two months in an elderly pa-
tient whilst maintaining a dose of four capsules per day
(subject 3, table 2).
C) In vitro effects on HSV
Herpes viruses were assessed for infectivity of human fi-
broblasts cells in vitro. Inhibition by GFS extract was noted
as shown in table 3.
D) T cell stimulation in vitro
GFS extract was assessed for effects on whole human T cell
preparation in vitro. After incubation with GFS extract or
mitogens PHA and ConA, for 72 hours the relative uptake
of chromium was assessed as a measure of mitogenicity.
The lowest concentration of GFS extract tested (25 mcg/
ml) exerted a four fold mitogenic effect on T cells, over
50% of the mitogenic potency of the known mitogens
PHA (six fold) and ConA (seven fold). Paradoxically, in-
creased concentrations of the whole extract showed de-
creasing effects on mitogenic activity. This may be
accounted for by the increasing physical inhibition due to
increased viscosity in the culture media, or the increasing
concentration of unidentified inhibitory components
present in the extract. Results are shown in Figure 1.
Additional studies illustrated little effect on NK cell activ-
ity and no effects on L929 fibroblast growth over 24 or 72
hours (results not shown). There was no bacterial contam-
ination of the GFS (results not shown), thus the presence
of bacterial lipopolysaccharides (which may also act as
mitogens) was ruled out.
Discussion
This study was carried out to assess the effects of GFS in
patient studies and in vitro.
GFS was ingested by patients suffering active or latent Her-
pes infections. Results indicated firstly, a positive effect on
healing, and secondly, inhibition of outbreaks in cases of
HSV-1, HSV-2, ACV resistant HSV-2, and zoster. There
were no adverse side effects noted, and GFS was well tol-
erated by all subjects. Reduced pain levels were noted in
some cases.
Table 3: IC50 for GFS whole extract as measured by infectivity of 
HSVI, HSV2 and HCMV (human cytomegalovirus) in human 
fibroblasts.
Herpes virus GFS 1:40 w/v
HSV – 1, strain F 3.1 ug/ml
HSV – 2, strain G 1.6 ug/ml
HCMV, AD169 2.5 ug/ml
HCMV, D16 2.5 ug/ml
Figure 1
T cell mitogenicity in the presence of GFS whole extract in
vitro. GFS extract assessed at 25, 125, 250 micrograms/ml
(as1%, 5% and 10% of culture medium from a stock solution
at 2.5 mg/ml). PHA and ConA were assessed at 1 mcg/ml. N
= 3 in all cases. Blue bars indicate average readings, red bars
indicate standard deviations.
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A particularly noteworthy result in this study was inhibi-
tion of an ACV resistant case of HSV-2. HSV-2 is a sexually
transmitted disease of increasing incidence [4]. In part,
this is due to the fact that partner transmission may occur
during asymptomatic shedding [4] or unrecognised mi-
nor outbreaks. Suppressive therapies such as ACV have
been tested for their ability to inhibit shedding [20]. How-
ever, for long-term use, non-toxic alternatives such as GFS
may be preferred by patients, who perceive long-term con-
ventional drug use as detrimental. In addition, GFS may
reduce the generation of resistant strains which arise
through prolonged use of drugs such as ACV.
GFS extract potently inhibited HSV and HCMV infection
of human cells, and stimulated human T cell proliferation
in vitro. In other studies [16,17] extracts were active
against clinical strains of HSV. These mechanisms may be
relevant to the observed clinical response.
Human T cell proliferation in vitro observed here concurs
with observations by Shan et al [18]. Shan found that in
the presence of various seaweed extracts including Undar-
ia, lymphocyte proliferation and cytotoxic T cell activity
was enhanced, but that NK cell activity was not. Cytotoxic
T cells play a prominent role in the immune response in
the local environment of HSV-2 infections [21], and have
been shown to be key elements of immune defence
against HSV-I and other viruses [22,23]. Thus the ob-
served T cell mitogenic effect caused by GFS in vitro may
be related to enhanced immunity in vivo.
Sulphated molecules with similarities to sulphated ga-
lactofucan, such as dermatan sulphate have been shown
to be present in plasma after oral ingestion [24]. Macro-
molecules are known to pass through the gut into plasma
and into lymph via the extensive gut lymphoid system
[25] where they may affect immune function. The gut
lymphoid system or 'GALT' comprises Peyers patches and
gut cryptopatches where different types of T cells and oth-
er immune cells participate in uptake or contact with gut
contents. T cell uptake or contact with GFS by either Pey-
ers patch or gut cryptopatch dwelling cells may result in
the proliferative response noted here in vitro. However,
immune indicators were not measured in this study.
Whilst further research is called for, the results obtained in
this study show that ingestion of GFS is associated with
resolution, reduced pain and outbreak inhibition of Her-
pes virus infections. Studies regarding uptake, immunos-
timulation and anti-viral effects of GFS are in progress.
Conclusions
The rise in nucleic acid inhibitor resistant strains of HSV-
2, and the need for less aggressive anti-viral therapies, in-
dicates a role for alternative therapeutic routes such as that
demonstrated here for GFS.
Ingestion of GFS has inhibitory effects on reactivation of
HSV and positively affects the resolution of active Herpes
infections. GFS has inhibitory effects on Herpes infectivity
in vitro and a T cell mitogenic effect in vitro.
The mechanism of inhibition of Herpes infections may
be, in part, mediated by galactofucan present in the GFS.
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